First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic

Telix Pharmaceuticals Limited is pleased to announce that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer theranostic APOMAB™, at the Royal Adelaide Hospital (‘RAH’). The clinical study which is being conducted by the Central Adelaide Local Health Network (‘CALHN’) is co-funded by Telix and strategic partner, AusHealth^®.

The study, which is being led by RAH Cancer Clinical Trials Unit Head Professor Michael Brown is a two-arm trial of an antibody that targets the La/SSB protein (APOMAB™), initially labelled with Zirconium-89 (⁸⁹Zr-APOMAB) to enable the biological and targeting properties of the agent to be evaluated using positron emission tomography (PET).

The target of APOMAB, the La/SSB protein, is specifically expressed by cancer cells that have been treated with chemotherapy and/or radiation, and the research objective of the study is to evaluate how well APOMAB is able to potentially deliver diagnostic and therapeutic targeted radiation to advanced lung or ovarian cancers.

To read the full ASX release please click here.